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Phosphoprotein enriched in diabetes (PED/PEA15)
promotes migration in hepatocellular carcinoma and
confers resistance to sorafenib
Cristina Quintavalle*,1, Sravanth Kumar Hindupur2, Luca Quagliata1, Pierlorenzo Pallante1,3, Cecilia Nigro4,5, Gerolama Condorelli3,6,
Jesper Bøje Andersen7, Katrin Elisabeth Tagscherer8, Wilfried Roth8, Francesco Beguinot4,5, Markus Hermann Heim9,
Charlotte Kiu Yan Ng1, Salvatore Piscuoglio1 and Matthias Sebastian Matter*,1
Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related death with limited treatment options and frequent
resistance to sorafenib, the only drug currently approved for first-line therapy. Therefore, better understanding of HCC tumor
biology and its resistance to treatment is urgently needed. Here, we analyzed the role of phosphoprotein enriched in diabetes
(PED) in HCC. PED has been shown to regulate cell proliferation, apoptosis and migration in several types of cancer. However, its
function in HCC has not been addressed yet. Our study revealed that both transcript and protein levels of PED were significantly
high in HCC compared with non-tumoral tissue. Clinico-pathological correlation revealed that PEDhigh HCCs showed an
enrichment of gene signatures associated with metastasis and poor prognosis. Further, we observed that PED overexpression
elevated the migration potential and PED silencing the decreased migration potential in liver cancer cell lines without effecting cell
proliferation. Interestingly, we found that PED expression was regulated by a hepatocyte specific nuclear factor, HNF4α. A
reduction of HNF4α induced an increase in PED expression and consequently, promoted cell migration in vitro. Finally, PED
reduced the antitumoral effect of sorafenib by inhibiting caspase-3/7 activity. In conclusion, our data suggest that PED has a
prominent role in HCC biology. It acts particularly on promoting cell migration and confers resistance to sorafenib treatment. PED
may be a novel target for HCC therapy and serve as a predictive marker for treatment response against sorafenib.
Cell Death and Disease (2017) 8, e3138; doi:10.1038/cddis.2017.512; published online 26 October 2017
Hepatocellular carcinoma (HCC) is the third most common
cause of cancer-related mortality worldwide.1,2 Unlike most
other malignancies, mortality from liver cancer has increased
significantly over the past 20 years and the medical and
economic burden of liver cancer will likely increase signifi-
cantly in Western populations over the next decades.3
Prognosis of HCC patients is poor and 5-year survival rate is
around 15%.2 Risk factors for HCC development include
chronic viral infection with Hepatitis B or C virus (HBV/HCV),
excessive alcohol abuse and non-alcoholic steatohepatitis
due to obesity and diabetes.2 Patients are only eligible for
potentially curative treatments such as surgical resection or
liver transplantation if HCC is detected at an early stage.2 For
systemic treatment, the only drug currently approved is
sorafenib, a multi-tyrosine kinase inhibitor.2 Although sorafe-
nib has been shown to increase overall survival in patients
with advanced stage HCC, response rate is poor,4 with only
2% of the patients achieving partial response, 71% achieving
stable disease and no patients achieving complete response
in the phase 3 SHARP trial (n= 602).4 Resistance to sorafenib
in HCC and other cancers have been associated, for example,
with elevated expression of angiogenesis-related genes,
fibroblast growth factor-1, NF-κB, upregulation of the targeted
MAPK/ERK pathway and epithelial–mesenchymal
transition.5–8 In addition, sorafenib is frequently accompanied
by moderate to severe side effects.2 Therefore, it will be
beneficial to identify patients who may benefit from sorafenib
therapy and to improve our understand of the mechanisms of
sorafenib resistance.
PED (phosphoprotein enriched in diabetes), also known as
PEA15 (phosphoprotein enriched in astrocytes 15), is a
ubiquitously expressed phosphoprotein, which was originally
identified in primary cultured astrocytes.9,10 PED has a
prominent role in diabetes and glucose metabolism.11
Furthermore, it modulates cellular processes such as pro-
liferation, apoptosis and migration in various cancer types
(e.g., breast, colon and esophageal cancers).11,12 Interest-
ingly, PED may act as a tumor promotor or tumor suppressor
and this function seems to depend on its phosphorylation
status.13 In its unphosphorylated form, PED binds ERK1/2
protein and prevents its subsequent activation. By contrast,
phosphorylation of PED at Ser104 and Ser116 releases
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ERK1/2, which in turn leads to tumor promotion with increased
cell proliferation and migration.12 In addition, PED phosphoryla-
tion at Ser116 facilitates its binding to Fas-associated death
domain protein (FADD). Consequently, FADD-mediated apopto-
sis is prevented and results in cell growth advantage.11 PED
levels are regulated by ubiquitination and proteasomal
degradation.14 Furthermore, transcription factor HNF4α has
been described as an upstream regulator of PED. By binding
to the PED promoter, HNF4α suppresses PED expression.15,16
Although the function of PED has been described in several
tumor entities, its role in HCC is currently unknown. Therefore,
we sought to determine PED expression in human HCC tissue
samples and analyze its functional role by performing in vitro
experiments. Additionally, we investigated its regulation, and
the impact of PED expression on sorafenib therapy.
Results
PED expression is increased in HCC. To determine the
expression level of PED in HCC we re-analyzed a published
gene expression microarray data set previously performed at
our hospital containing human HCC samples and their
corresponding non-tumoral liver tissues (n=59 pairs).17
The mean age of the HCC patients was 64 years. 88% of
patients were male, had underlying liver cirrhosis and
suffered from chronic viral liver disease (HCV and/or HBV)
or alcohol abuse.17 Mean PED expression in the tumors was
significantly elevated compared with the matched non-
tumoral liver tissues (Figure 1a). However, not all HCC
samples showed an increase of PED expression compared
with the matched non-tumoral liver tissues, with 28.8% of the
tumor samples showing an increase of two-fold or higher in
comparison to the matched non-tumoral counterparts. To
confirm the microarray results, we measured PED mRNA
expression by qRT-PCR in the same cohort of patient
samples with sufficient RNA left (n=24 paired). Consistently,
PED mRNA expression in the tumors was significantly higher
than the non-tumoral liver tissue (Supplementary Figure 2). In
addition, we measured PED mRNA expression by qRT-PCR
in HCC tumor samples of an independent patient cohort
(n=14). The patients had a mean age of 69 years. 79% of the
patients were male, had underlying liver cirrhosis and
suffered from chronic viral liver disease (HCV and/or HBV)
or alcohol abuse. In comparison to the non-tumoral liver
tissues (n=10) and in line with the microarray results, PED
expression was again increased in the HCC samples
(Figure 1b) and 43% of the tumor samples showed an
increase of two-fold or more in comparison to the mean of
PED expression in the non-tumoral tissues. Furthermore, we
performed immunohistochemistry for PED on a tissue
microarray (TMA) containing formalin fixed and paraffin
embedded HCC samples (n= 45) and non-tumoral control
liver tissue (n= 20) (Table 1). Cytoplasmic staining intensity
was graded as ‘0’ for negative staining, ‘1’ for weak, ‘2’ for
moderate and ‘3’ for strong staining (Figure 1c;
Supplementary Figure 1). PED was expressed (staining
intensity 1, 2 or 3) in almost half (47%) of the HCC samples
and less frequently in the non-tumoral liver tissues (15%)
(Figures 1c and d). In addition, we determined the
percentage of cells with positive staining to calculate the h-
score (staining intensity × percentage of positive tumor cells).
Consistently, the h-score was significantly higher in the HCC
samples than in the non-tumoral control liver tissues
(Figure 1d). In accordance, western blot analysis revealed a
higher level of total PED in HCC (n= 7) compared with
the adjacent non-tumoral liver (Figures 1e and 4d;
Supplementary Figure 2). Interestingly, PED was increased
in its bi-phosphorylated form with phosphorylation at both
Ser104 and Ser116 residues (Figure 1e).
In conclusion, our data demonstrate higher PED expression
in HCC samples in comparison to non-tumoral liver tissue at
mRNA and protein levels.
Figure 1 PED is overexpressed in HCC samples. (a) PED expression levels in
HCC samples and their matched non-tumoral (NT) counterpart measured by an
mRNA gene expression microarray. Data are reported as probe intensity. (b) PED
mRNA was measured by qRT-PCR in a separate cohort of 14 HCC patients and
compared with the 10 available non-tumoral counterpart. 18 S was used as internal
control and 2−ΔΔCt formula was applied to determine relative expression levels.
Statistical analysis (a,b) with paired Student t-test. (c) Representative immunohis-
tochemical staining from an HCC tumor (left) with positive (3+) PED staining
and non-tumoral liver tissue (NT) showing negative PED staining (right). Scale
bar= 20 μm. (d) Percentage and h-score (staining intensity × percentage of
positive tumor cells) of PED positivity in HCC samples and non-tumoral (NT) liver
tissues by immunohistochemistry. (e) Western blot analysis of total PED and
phosphorylated PED (PED S116 and PED S104) in two HCC patient samples and
their corresponding NT control tissues. Calnexin was used as internal control.
*Po0.05, ***Po0.001
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PED is associated with metastasis formation and poor
prognosis of HCC patients. Next, we correlated PED
expression in the gene expression microarray data generated
from the 59 patients with clinico-pathological data. PED was
significantly (Po0.0001; Mann–Whitney U-test) overex-
pressed in poorly differentiated HCCs (Edmondson grades
III and IV) than in well-differentiated HCCs (Edmondson
grades I and II; Figure 2a). Interestingly, PED was also
significantly overexpressed (P=0.014, Mann–Whitney U-
test) in patients who had metastasis at the time of biopsy
(Figure 2b). In accordance, gene set enrichment analysis
(GSEA) using two previously published metastasis-
associated gene signatures derived from HCC tumor
samples18 showed significant enrichment in tumor samples
with high PED expression (PEDhigh, Figure 2c). In addition, a
gene signature associated with poor survival in HCC
patients19 was enriched in PEDhigh samples (Figure 2d). By
contrast, a gene signature associated with good survival was
enriched in samples with low PED expression (PEDlow). In
line with these results, survival analysis using data from
TCGA (Bioprofiling.de20) revealed a significant worse survival
with PEDhigh (n=133) tumors in comparison to PEDlow
tumors (n=112) in a subgroup of patients (n=252) with N0
tumor stage (Figure 2e, P=0.0154). Association with worse
survival was also observed in subgroups of patients
characterizied by a T3 stage (PEDhigh n= 23 versus PEDlow
n= 20 P=0.0204), M0 stage ( PEDhigh n= 133 versus
PEDlow n= 112 P= 0.0196) and IIIa stage group (PEDhigh
n= 33 versus PEDlow n=27 P=0.048). However, survival
analysis covering all patients included by TCGA (n=442) and
also with our cohort of 59 patients did not reveal a significant
association of PED expression with patient survival (data not
shown). Altogether, these results demonstrate that high PED
expression is associated with high edmondson grade,
metastasis formation and at at least in part with poor survival.
PED promotes cell migration. To gain insight into the
functional role of PED in hepatocarcinogenesis, we per-
formed in vitro experiments. First, we measured PED protein
expression by western blot in ten different liver cancer cell
lines (Figure 3a, quantification Supplementary Figure 3A).
PED expression was variable among these cell lines and for
example, SNU-449, SNU-182 and HLE cells showed high
PED expression, whereas Hep3B and HuH-1 cells had low
PED expression. In addition, we measured PED mRNA
expression by qRT-PCR in 21 different liver cancer cell lines,
which revealed similar variability of PED expression
(Supplementary Figure 3B).
Table 1 Clinico-pathological features of the TMA cohort
Hepatocellular carcinoma (n=45) Frequency (%)














Figure 2 PED is associated with metastasis formation and poor patient survival.
PED probe intensities from the gene expression microarrays of 59 HCC samples
were compared between (a) those with low (I–II) or high (III–IV) Edmondson grades,
and between (b) those with or without metastasis at the time of diagnosis. Statistical
analysis (a,b) with Mann–Whitney U-test. (c) GSEA using a HCC metastasis-
associated gene signature18 with downregulated (Metastasis DN) or upregulated
(Metastasis UP) genes between HCC samples with high PED expression (PED high)
or low PED expression (PED low). (d) GSEA using a gene signature from HCC
patients with poor or good survival19 between HCC samples with high PED
expression (PED high) or low PED expression (PED low). NES: normalized
enrichment score. FDR: false discovery rate. (e) Survival analysis (Kaplan–Meyer) of
HCC patients by calculating distribution in a previously published data set
(Bioprofiling.de20) after stratification for high (n= 127) and low (n= 112) tumoral
PED expression. ** Po0.01
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For functional analysis, we overexpressed PED by transfec-
tion with a vector (PED-MYC-tagged) and reduced PED
expression by siRNA (Supplementary Figures 3C,D). We first
measured cell proliferation, which remained unchanged after
modulating PED expression in HuH-7 and SNU-449 cell lines
(Figure 3b). By contrast, cell migration, as assessed by transwell
plates, was promoted after overexpressing PED in HLE,
SNU-449 and HuH-7 cell lines (Figure 3c) and cell migration
was decreased after silencing PED by siRNA (Figure 3c).
Therefore, our data suggest that PED in HCC has a role in
cell migration, which may contribute to metastasis formation.
In contrast, no action recognized on cell growth.
PED expression is regulated by HNF4α. Earlier studies
have shown that HNF4α supresses PED expression at the
mRNA and protein levels by binding to its promoter.15,16
Therefore, we first reconfirmed that HNF4α binds to the PED
promotor in HCC, as revealed by a luciferase assay in
SNU-449 cell lines (Figure 4a). Next, we analyzed HNF4α
and PED expression in our gene expression microarray of the
59 HCC and matched non-tumoral liver tissues.17 We
observed a significant inverse correlation between HNF4α
and PED mRNA expression in the HCCs (Figure 4b).
Interestingly, we also observed an inverse correlation between
HNF4α and PED mRNA expression in the non-tumoral liver
tissues of the HCC patients, suggesting that PED regulation by
HNF4α is not restricted to liver cancer cells (Figure 4c). In
accordance, western blots of PED and HNF4α in tumoral and
non-tumoral liver tissues of HCC patients also showed an
inverse correlation between these two proteins (Figure 4d).
Similarly, analysis of a publicly available transcriptome array of
transgenic mice (GEO GSE34581)21 revealed that hepatic
PED expression increased after specifically depleting HNF4α
in the liver (Supplementary Figure 4A). Moreover, there was an
inverse correlation between hepatic PED and HNF4α expres-
sion (Supplementary Figure 4B). We did not observe a
significant difference in HNF4α mRNA expression between
tumoral and matched non-tumoral tissue in our transcriptome
microarray data set (Supplementary Figure 4C). Yet, as
described before, HNF4α expression significantly decreased
in non-tumoral, mostly cirrhotic liver tissue, in comparison to
healthy liver samples (n=5) (Supplementary Figure 4C),
supporting its role in hepatocarcinogenesis.21,22
To investigate if HNF4α directly regulates PED expression, we
reducedHNF4α expression by siRNA in two different liver cancer
cell lines (HuH-7 and PLC/PRF-5). After reducing HNF4α,
protein (Figure 4e) and mRNA levels (Figure 4f) of PED
increased in both cell lines. Next, we wanted to test if HNF4α
regulates cell migration23,24 through PED. Therefore, we
performed a rescue experiment and silenced PED and HNF4α
simultaneously in SNU-449 cells (Figure 4g). As expected,
silencing of HNF4α alone increased, whereas silencing of PED
Figure 3 PEDmodulates cell migration. (a) Western blot analysis of PED protein expression in 10 different HCC cell lines. β-Actin was used as loading control. (b) HuH-7 and
SNU-449 cells were transfected with PED-MYC or an empty control vector as wells as with siRNA against PED (siRNA PED) or control siRNA. Cell growth properties were
evaluated by using xCELLigence instrument at the time indicated. Data are reported as mean± S.D. of two independent experiments performed at least in triplicate. Difference
was evaluated between PED overexpressing (PED-MYC), PED silenced (siRNA PED), empty vector transfected and a siRNA control transfected cells (two-way ANOVA test).
(c) HLE, SNU-449 and HuH-7 cell lines were transfected with a vector overexpressing PED (PED-MYC) or empty control vector, siRNA against PED (siRNA PED) or siRNA
control. Migration was assessed using a transwell assay after 24 h. One representative image of crystal violet stained cells at 100 × is shown above and quantification by
colorimetry below. ***Po0.001, ****Po0.0001
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Figure 4 PED is inversely correlated to HNF4α expression. (a) SNU-449 cells were co-transfected with 100 ng of pPED477 PED promoter-luciferase or pGL3 basic construct
and treated with siRNA against HNF4α or siRNA control. Luciferase activity was normalized for Renilla activity and is presented as mean± S.D. A representative experiment in
triplicate is shown. (b,c) PED expression levels in HCC samples (b; n= 59) or corresponding non-tumoral liver tissue (c, n= 59) were correlated with HNF4α expression.
Correlation was calculated by Spearman test. Data are reported as probe intensity of an mRNA transcriptome array. (d) Western blot analysis for HNF4α and PED in two HCC
patient tumor samples and their corresponding non-tumoral (NT) tissues. Calnexin was used as loading control. Arrow: canonical full length HNF4α (52 kDa); other bands are
isoforms or truncated forms of the protein. (e,f) HuH-7 and PLC/PRF/5 cell lines were transfected with siRNA against HNF4α (siHNF4α) or siRNA control. After 72 h the protein
expression of HNF4α and PED was measured by western blot (e) and β-actin served as control. mRNA expression was measured by qPCR (f) using RNA 18 S as internal control
at 48 h for HuH-7 and 72 h for PLC/PRF/5. Data are reported as mean± S.D. of two independent experiments performed in triplicate. (g) SNU-449 cells were transfected with
siRNA against HNF4α or siRNA against PED alone or in combination, or siRNA control, as indicated. Migration was assessed by CIM plate with xCELLigence apparatus after
12 h and 24 h. Data are reported as mean± S.D. of two independent experiments performed in triplicate. (h) Western blot analysis of pERKThr202/Tyr204 and ERK in SNU-449,
Hep3B and HuH-7 cell lines transfected with PED-MYC. β-Actin was used as loading control. (i) pERKThr202/Tyr204 expression in two HCC patients and their non-tumoral
counterpart. Calnexin was used as loading control. *Po0.05, **Po0.01, ****Po0.0001
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alone reduced cell migration. A combination of PED and HNF4α
silencing reverted the suppressive effect of siRNA against PED
and cell migration was similar to control transfected cells.
Therefore, our experiments indicate that HNF4α regulates cell
migration through PED in liver cancer cells (Figure 4g).
In addition, we wanted to analyze cellular processes
downstream of PED. Earlier studies have revealed that
activation of PED leads to an increase of ERK
phosphorylation.25–28 Therefore, we increased PED expres-
sion by PED-MYC transfection in three different cell lines
(SNU-449, Hep3B, HuH-7) and measured total ERK and
pERKThr202/Tyr204 expression by western blot. Whereas total
ERK expression remained similar, there was a clear increase
of pERKThr202/Tyr204 after upregulation of PED (Figure 4h).
Detection of pERKThr202/Tyr204 in human HCC tissue samples
was technically difficult, but one out of 2 samples already
analyzed for PED expression in Figure 4d showed an increase
of pERKThr202/Tyr204 in the tumoral tissue (Figure 4i). In
conclusion, our results confirm that pERK is one of the
downstream proteins activated by PED.
PED confers resistance to sorafenib. Earlier studies in
non-HCC cancer cell lines such as breast cancer29 and colon
cancer26 have shown that PED confers resistance to che-
motherapy. Therefore, we tested the role of PED in HCC cell
lines treated with the multi-kinase inhibitor sorafenib. Sorafenib
treatment slightly decreased the proliferation rate of HuH-7 and
SNU-449 cells in vitro (Figure 5a). However, the effect of
sorafenib treatment on cell proliferation became significantly
more pronounced after silencing PED expression by siRNA
(Figure 5a). Vice versa, upregulation of PED in HuH-7 and
Hep3B cells by transfection with a PED-MYC vector antag-
onized the effect of sorafenib on cell viability, whereas sorafenib
clearly reduced cell viability in empty vector transfected cells
(Figure 5b). Therefore, PED counteracts the effect of sorafenib
in HCC cell lines. Western blot and a caspase assay further
indicated that the executor caspase-3 (Figure 5c) and caspases
3/7 respectively (Figure 5d) were upregulated after reduction of
PED and downregulated after increase of PED in sorafenib
treated HuH-7 cells. Therefore, inhibition of apoptosis may be
one of the mechanisms by which PED confers resistance to
sorafenib treatment
Finally, we exposed ten different HCC cell lines to sorafenib
and correlated response rate to PED expression quantified by
western blot (Figure 3a; Supplementary Figure 3B;
Supplementary Figure 5A). Some cell lines, which were highly
sensitive to sorafenib (e.g., HuH-7 and Hep3B) had low PED
expression, and other cell lines, which were highly resistant to
sorafenib (e.g., SNU-182, PLC/PRF-5 and SNU-449) had high
PED expression. However, we did not observe a significant
correlation between PED protein expression and sorafenib
sensitivity (Supplementary Figure 5B). Therefore, our results
confirm that, besides PED, other sorafenib resistance
mechanisms exist in HCC cell lines.30
Discussion
The multifunctional phosphoprotein PED has an important
role in several cancer entities, yet its expression and function
in HCC has not been investigated yet. Our study revealed that
PED is overexpressed in HCC at mRNA and protein level. In
addition, HCC samples with high PED expression showed an
enrichment of a gene signature with poor prognosis and was
further associated with shorter survival. Similarly, PED has
been reported to be overexpressed in other cancer types such
as breast cancer,29 lung cancer31 and esophageal carcinoma,32
where it promotes tumor growth33–35 and is associated with poor
survival.32 By contrast, it was associated with good prognosis in
ovarian cancer when overexpressed.25 This difference is mainly
explained by its phosphorylation status. PED was unpho-
sphorylated in ovarian cancer.36 In contrast, PED was phos-
phorylated at both serine sites (pSer116, pSer104) in our study.
This phosphorylation status indicates an increased ERK1/2
activity and an anti-apoptotic role through FADD.12 Therefore, as
described before, the phosphorylation status determines if PED
acts as a tumor promotor or a tumor suppressor.13
Our functional in vitro experiments revealed that cell
proliferation remained unaffected by PED in liver cancer cell
lines. By contrast, cell migration was increased after upregula-
tion of PED and, vice versa, decreased after PED reduction. In
line with this observation, we noted that HCC samples from
patients with metastasis showed higher PED expression.
Moreover, PEDhigh tumors showed an enrichement of a gene
signature associated with HCC metastasis.18 Therefore, our
results suggest that PEDmay promotemetastasis formation in
HCC by increasing cell migration. Furthermore, PED could be
a potential target to prevent metastasis formation, which is
associated with very poor prognosis.37 Several earlier studies
have already shown that PED exerts its effect onmigration and
invasion by ERK1/2 regulation.26,38,39 If PED is phosphory-
lated, as in our study, ERK1/2 is activated with ensuing
increase in pERK, which promotes invasion and migration.38
By contrast, if PED is unphosphorylated, ERK is sequestered
and migration and invasion is reduced, as has been shown for
example in colon cancer and neuroblastoma.26,40 We further
confirmed that HNF4α is an upstream regulator of PED in HCC
and binds to the PED promoter. In vitro silencing of HNF4α
increased PED expression with ensuing promotion of cellular
migration. In accordance, we detected an inverse correlation
between HNF4α and PED expression in HCC samples. As a
transcription factor, HNF4α controls hepatic differentiation, but
it also inhibits hepatic proliferation and controls epithelial-to-
mesenchymal transition in liver tumors.41–44 Not unexpectedly,
HNF4α has been shown to have an important role in
hepatocarcinogenesis. Upon treatment with diethyl nitrosa-
mine, mice lacking HNF4α have an increased liver tumor
development. In contrast, rats overexpressing HNF4α have a
reduced liver tumor development.22,41 By inhibition of the
transcription of epithelial-to-mesenchymal transition-
regulatory genes such as Snail and Slug, HNF4α prevents
migration and invasion in HCC.43,44 Therefore, we propose a
novel link between HNF4α and PED expression in HCC. The
downregulation of HNF4α during hepatocarcinogenesis leads
to an increase of total PED, which becomes phosphorylated.
Consequently, ERK1/2 is activated and promotes tumor
development and in particular cellular migration.
PEDhas been shown tomediate chemo resistance in various
cancer types such as for example colon cancer and breast
cancer.26,29 In HCC, sorafenib is currently the only drug
approved for systemic treatment.45 However, it goes frequently
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along with adverse side effects and resistance.8 Furthermore, it
has limited treatment efficacy. Interestingly, silencing of PED
sensitized HuH-7 and SNU-449 cells to sorafenib treatment,
whereas upregulation of PED counteracted sorafenib effect in
Hep3B and HuH-7 cells. In detail analysis suggest that PED
modulates apoptotic caspase cascade and indicates that the
observed PED overexpression in HCC may prevent the
apoptotic effects of sorafenib treatment. In line with our
observations on the functional role of PED, earlier studies have
revealed that epithelial–mesenchymal transition as well as
ERK1/2 are involved in sorafenib resistance.8 In conclusion,
measuring PED expression could represent a marker to predict
sorafenib treatment response.
In summary, our study shows that high PED expression in
HCC is associated with poor survival and promotesmigration of
cancer cells. Furthermore, PED expression reduces the effect
of sorafenib, which opens new perspectives in understanding
sorafenib resistance in HCC patients. Furthermore, it suggests
that co-targeting of PED may improve the efficacy of sorafenib.
Materials and Methods
Patients. All tissue specimens were collected from the archive at the Institute of
Pathology, University Hospital of Basel, Switzerland. The collection protocol
conforms to ethical guidelines of the 1975 Declaration of Helsinki and has been
approved by the ethics committee of the Kanton Basel (Ethikkommission beider
Basel). Written informed consent was obtained from all participants.
Tissue microarray. For TMA construction, a representative tumor area was
selected on an hematoxylin and eosin (H&E)-stained slide of the donor block. A
core punch with a diameter of 0.6 mm was taken from the tumor (n= 45) and in
selected cases from the non-tumoral liver tissue (n= 20) of each slide. Core
punches were transferred to a new paraffin recipient block using a programmed
tissue arrayer (Beecher Instruments, Silver Spring, MD, USA).
Figure 5 PED confers resistance to sorafenib therapy. (a) HuH-7 and SNU-449 cells were transfected with siRNA against PED or siRNA control. Afterwards, HuH-7 and
SNU-449 cells were treated with 10 μM and 20 μm respectively of sorafenib or left untreated. Cell growth was evaluated by using the xCELLigence instrument at the indicated
time. Data are reported as mean±S.D. of two independent experiments performed in triplicate. (b) HuH-7 and Hep3B cells were transfected with PED-MYC vector for 24 h and
then seeded in a 96-well plate. 10 μm of sorafenib was added and 24 h or 48 h later, cell viability was measured by a MTT assay. Data are reported as mean±S.D. of two
independent experiments perfomed in triplicate. (c) HuH-7 cells were transfected with PED-MYC or empty vector (Ctrl) and siRNA against PED or siRNA control (Ctrl), as
indicated. After 24 h, cells were treated with 10 μM or 7 μM sorafenib, respectively, for 48 h and caspase-3 activation was measured by western blot. (d) HuH-7 cells were
transfected with siRNA against PED or control siRNA. Afterwards, cells were treated with 10 μM sorafenib and 48 h later caspase-3/7 assay activation was measured. Data are
reported as mean±SD of one experiment performed in triplicate. *Po0.1, **Po0.01, ***Po0.001, ****Po0.0001
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Immunohistochemistry. For immunohistochemistry, 4 μm slides obtained form
the TMA were stained with a polyclonal sheep PED antibody (AF5588, R&D System,
Minneapolis, USA) using the Dako Real Detection System (Agilent Technologies, Santa
Clara, CA, USA). In brief, sections were first blocked with Dako Envison FLEX/
Peroxidase-Blocking Reagent for 5 min and stained thereafter with primary anti-PED
antibody (1:50) for 30 min. After washing, biotinylated secondary antibody was added
(anti-sheep IgG, Vector Laboratories, Burlingame, CA, USA; BA-6000, dilution 1:1000)
and detected using streptavidin-horseradish peroxidase conjugate (Agilent Technolo-
gies) and DAB+ Chromogen (Agilent Technologies). PED cytoplasmic staining intensity
was evaluated by a board-certified pathologists with expertise in hepatopathology
(MSM) and graded semi-quantitatively into: 0 for negative staining, 1+ for weak positive
staining, 2+ for moderate positive staining and 3+ for strong positive staining, as shown
representatively in Supplementary Figure 1. The h-score was calculated by multiplying
staining intensity with percentage of positive tumor cells.
RNA extraction and quantitative real-time PCR. Total RNAs from
fresh frozen tissues were extracted using Trizol (LuBioScience GMbH, Lucerne, CH,
USA) according to the manufacturer’s protocol. 500 ng of total RNA were reverse
transcribed using first cDNA synthesis beads (GE Healthcare, Little Chalfont, UK).
mRNa expression of PED and 18 SRNA (used as an internal reference) was
assessed using the TaqMan® Probe-Based Gene Expression Analysis and the
(Assay-on-Demand: Hs00269428_m1 and Hs99999901_s1, respectively; Life
Technologies, ThermoFisher Scientific) according to the manufacturer’s protocol.
HNF4α mRNA quantification was performed with SybrGreen Master Mix
(ThermoFisher Scientific) using the following primers covering the gene of interest
and the reference control (18 S): HNF4α FWD 5′–3′: TCAACCCGAGAAAACAAA;
HNF4α REV 5′–3′: ACCTGCTCTACCAGCCAGAA; 18 S-FWD: 5′–3′: AACCCG
TTGAACCCCATT; 18S-REV 5′–3′: CCATCCAATCGGTAGTAGCG. For relative
quantization the 2(−ΔCT) or the 2(−ΔΔCT) method was employed as previously
described.46 All reverse-transcriptase reactions, including no-template controls, were
run in triplicate on an Applied Biosystem Viia VII real-time PCR system and target
gene expression levels were normalized to thr reference gene. Data analysis was
performed using the build-in Applied Biosystem dedicated software (Life
Technologies, ThermoFisher Scientific).
Protein isolation and western blotting. Protein extraction and western
blotting were performed as previously described.47 Primary antibodies used were:
anti-β-Actin (Sigma-Aldrich, St. Louis, MO, USA), anti-PED,48 anti-Calnexin
(CellSignalling Technology, Basel), anti-PED S116 (ThermoFisher Scientific) anti-
PED S104 (Cell Signaling Technologies, Danver, MA USA), anti-Caspase-3 (Cell
Signaling Technologies, Danver, MA USA), anti-total ERK and anti-phopsho ERK
(Cell Signaling Technologies), and anti-HNF4α (Santacruz Biotechnologies,
Heidelberg, Germany for cell lines and Novus Biological, Oxon, England, UK for
human samples). Blots were visualized by using the Azure c3000 (Azure
Biosystems, Inc., Dublin, CA, USA).
For human tissue samples the following protocol was used. Frozen tissue was
crushed into a fine powder in metal mortar (constructed in-house) cooled on dry ice
and resuspended in 8 M Urea (Applichem, A1086) containing 50 mM Tris-HCl,
150 mM NaCl, 1 mM PMSF, 1X Complete Mini Protease Inhibitors from Roche
(Roche, Basel, Switzerland), 1X PhosSTOP (Roche) and homogenized using a
Polytron (PT 10-35 GT, Kinematica, Lucerne, Switzerland) at 500 rpm for 2 min on
ice. The lysates were then subjected to rotation at 4 °C with intermittent vigorous
vortexing and then were centrifuged at 10 000 × g for 10 min at 4 °C to remove cell
debris. The protein concentration in the supernatants was determined by the Bradford
assay using bovine albumin as reference. Human tissue samples were all from
resection specimens of patients operated for HCC. Mean age of patients was 66.8
years, mean tumor diameter was 9.6 cm.
Protein levels were quantitatively assessed by a densitometric analysis using
ImageJ analysis software (Rasband, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, MD, USA, http://imagej.nih.gov/ij/, 1997–2016).
Cell lines and transfection. All cells were purchased from the American
Type Culture Collection (ATCC) and maintained in 5% CO2-humidified atmosphere
at 37 °C. Media were supplemented with 10% heat-inactivated fetal bovine serum
(FBS) 10%, 2 mM Glutamine and 100 U/ml penicillin/streptomycin. Transfections
were performed using Lipofectamine 3000 (Life Technologies, ThermoFisher
Scientific, Reinach, Switzerland) according to manufacturer’s protocol. For PED
overexpression, the pcDNA-3-PED-MYC48 plasmid was used. PED silencing was
achieved with On-Target Smart Pool for PEA15 (Ge Dharmacon, Freiburg im
Breisgau, Germany) and the relative negative control was used. For HNF4α
silencing, a specific siRNA and its relative control were used (SantaCruz
Biotechnologies, Heidelberg, Germany). All cell lines were confirmed negative for
mycoplasma infection using the PCR-based Universal Mycoplasma Detection kit
(American Type Culture Collection, Manassas, VA, USA) as previously described.47
Proliferation assay and sorafenib sensitivity. Cell Proliferation was
assessed using the xCELLigence system (OLS, Basel, Switzerland). 5000 cells per
well were plated and then transfected 24 h after. For sorafenib treatment, 10 or
20 μM as indicated of sorafenib was added to the cells 24 h after transfection. For
screening sorafenib sensitivity in HCC cell lines, including in HuH-7 and Hep3B cells
upon PED overexpression, the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay was adopted.
Luciferase reporter assay. pGL3 basic vector, PED-477 luciferase promoter
and TK-renilla luciferase plasmid hve been described before.16 SNU-449 cells were
transfected in 96-well plate with 20 ng of Renilla luciferase and 100 ng of Firefly
Luciferase constructs in combination or not with the siRNA for HNF4α using
lipofectamine 3000 following the manufacturers protocol. After 48 h luciferase assay
was performed using Dual-GLO Luciferase® Assay System (Promega, Madison, WI,
USA) on a multiwall plate reader (Synergy H1, Biotek, Luzern, Switzerland).
Transfection of each construct was performed in triplicate. Ratios of Renilla luciferase
readings to Firefly luciferase readings were taken for each experimental point.
Caspase-3/7 activity measurement. 5x103 cells were seeded in a 96-well
plate and then transfected after 24 h. The day after 10 μM of sorafenib was added
to the plate fand then caspase-3/7 activity was measured after 48 h with the Apo-
ONE® Homogeneous Caspase-3/7 assay (Promega, Dübendorf, Switzerland)
according to the manufacture instruction.
Migration assay. Transwell Permeable Supports, 8 μm pore size (Corning
Incorporate, Corning, USA) were used to perform migration assay. 105 cells were
resuspended in medium with 1% FBS and seeded in the upper chamber. After 24 h,
cells were stained with 0.1% Crystal Violet in 25% methanol and then eluted in 1%
SDS.49 For rescue experiment, migration was assessed with CIM plates using the
xCELLigence system (OLS, Basel, Switzerland). 48 h after transfection, cells were
detached and counted. 3x104 cells were plated in each well according to
manufacturer’s instruction and migration was assessed 12 and 24 h after seeding.
PED mRNA expression analysis by microarray and GSEA. Data
from the gene expression profiling (GeneChip
®
Human Gene 1.0STarray, Affymetrix)
of 59 needle biopsies from HCC tissues and their corresponding non-tumoral liver
tissues was obtained from a previous study17 and re-analyzed using the Qlucore
software (Lund, Sweden). GSEA50 was performed to assess the enrichment of
previously published metastasis or prognosis-associated gene signatures between
PEDhigh and PEDlow HCCs. A two-fold change or more in PED expression between
tumoral and non-tumoral tissues was regarded as cut-off to classify patients into
PEDhigh and PEDlow subclasses.
Statistical analysis. Chi-square test (χ2-test), Fisher's exact test and Mann–
Whitney U-test for nonparametric variables and Student’s t-test for parametric
variables were used for statistical analyses. Patient survival was assessed using the
Kaplan–Meier method and the log-rank test. All tests were two-sided with P-values
o0.05 were considered statistically significant. Analyses were performed using
GraphPad PRISM (GraphPad Software, La Jolla, USA).
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